{
  "guideline" : {
    "@id" : "https://pharmgkb.org/guidelineAnnotation/PA166202721",
    "@context" : "https://api.pharmgkb.org/jsonld/guidelineAnnotation.jsonld",
    "objCls" : "Guideline Annotation",
    "id" : "PA166202721",
    "name" : "Annotation of PRO Guideline for capecitabine,fluorouracil and DPYD",
    "cancerGenome" : false,
    "crossReferences" : [ ],
    "descriptiveVideoId" : "",
    "guidelineGenes" : [ ],
    "history" : [ {
      "id" : 1451136660,
      "date" : "2020-05-13T00:00:00-07:00",
      "description" : "Approving to live",
      "type" : "Note",
      "version" : 0
    } ],
    "literature" : [ {"@id":"https://pharmgkb.org/literature/15109202","@context":"https://api.pharmgkb.org/jsonld/literature.jsonld","id":15109202,"resourceId":"28262261","title":"Pharmacogenetics of anti-cancer drugs: State of the art and implementation - recommendations of the French National Network of Pharmacogenetics.","_sameAs":"https://www.ncbi.nlm.nih.gov/pubmed/28262261","crossReferences":[{"@id":"https://pharmgkb.org/crossReference/pubMed/28262261","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1451127600,"resource":"PubMed","resourceId":"28262261","_url":"https://www.ncbi.nlm.nih.gov/pubmed/28262261"},{"@id":"https://pharmgkb.org/crossReference/doi/10.1016/j.therap.2017.01.005","@context":"https://api.pharmgkb.org/jsonld/crossReference.jsonld","id":1451127601,"resource":"DOI","resourceId":"10.1016/j.therap.2017.01.005","_url":"http://dx.doi.org/10.1016%2Fj.therap.2017.01.005"}],"objCls":"Literature","type":"Article"} ],
    "pediatric" : false,
    "recommendation" : true,
    "relatedAlleles" : [ {
      "@id" : "https://pharmgkb.org/variant/PA166153760",
      "@context" : "https://api.pharmgkb.org/jsonld/variant.jsonld",
      "objCls" : "Variant",
      "id" : "PA166153760",
      "symbol" : "rs3918290",
      "name" : "rs3918290",
      "version" : 5
    }, {
      "@id" : "https://pharmgkb.org/variant/PA166153888",
      "@context" : "https://api.pharmgkb.org/jsonld/variant.jsonld",
      "objCls" : "Variant",
      "id" : "PA166153888",
      "symbol" : "rs55886062",
      "name" : "rs55886062",
      "version" : 4
    }, {
      "@id" : "https://pharmgkb.org/variant/PA166153889",
      "@context" : "https://api.pharmgkb.org/jsonld/variant.jsonld",
      "objCls" : "Variant",
      "id" : "PA166153889",
      "symbol" : "rs56038477",
      "name" : "rs56038477",
      "version" : 3
    }, {
      "@id" : "https://pharmgkb.org/variant/PA166153895",
      "@context" : "https://api.pharmgkb.org/jsonld/variant.jsonld",
      "objCls" : "Variant",
      "id" : "PA166153895",
      "symbol" : "rs67376798",
      "name" : "rs67376798",
      "version" : 4
    } ],
    "relatedChemicals" : [ {
      "@id" : "https://pharmgkb.org/chemical/PA448771",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA448771",
      "name" : "capecitabine",
      "version" : 19
    }, {
      "@id" : "https://pharmgkb.org/chemical/PA128406956",
      "@context" : "https://api.pharmgkb.org/jsonld/chemical.jsonld",
      "objCls" : "Chemical",
      "id" : "PA128406956",
      "name" : "fluorouracil",
      "version" : 15
    } ],
    "relatedGenes" : [ {
      "@id" : "https://pharmgkb.org/gene/PA145",
      "@context" : "https://api.pharmgkb.org/jsonld/gene.jsonld",
      "objCls" : "Gene",
      "id" : "PA145",
      "symbol" : "DPYD",
      "name" : "dihydropyrimidine dehydrogenase",
      "version" : 6907
    } ],
    "source" : "Professional Society",
    "summaryMarkdown" : {
      "id" : 1451129280,
      "html" : "<p>The French National Network of Pharmacogenetics (Réseau national de pharmacogénétique (RNPGx)) recommends testing for DPYD deficiency before initiating a treatment regimen based on 5-FU or capecitabine, with dose reductions for DPYD partial deficiency and contraindicates fluoropyrimidines in patients with complete deficiency.</p>\n",
      "version" : 0
    },
    "summaryVideoId" : "",
    "terms" : [ ],
    "textMarkdown" : {
      "id" : 1451129281,
      "html" : "<p>The French National Network of Pharmacogenetics (RNPGx) publication about the state of the art and clinical implementation — recommendations from the French National Network of Pharmacogenetics for anti-cancer drugs states:</p>\n<blockquote class=\"blockquote\">\n<p>The RNPGx recommends screening for <a href=\"/gene/PA145\">DPYD</a> deficiency\nbefore initiating a treatment regimen based on 5-FU or\ncapecitabine, especially in patients at risk of toxicity\n(protocols using bolus administration or high-doses, fluoropyrimidine toxicity reported in a family member) or in an\nadjuvant situation.</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>Phenotyping by determining the serum UH2/U ratio or\nlymphocyte DPD activity is considered essential</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>If phenotyping is not available, genotyping should be\nperformed... genotyping to search for\nthe three consensual variants as proposed by the CPIC\n(*2A <a href=\"/variant/PA166153760\">rs3918290</a>, *13 <a href=\"/variant/PA166153888\">rs55886062</a>, and c.2846A&gt;T <a href=\"/variant/PA166153895\">rs67376798</a>) is advisable.</p>\n</blockquote>\n<blockquote class=\"blockquote\">\n<p>If genotyping predicts partial deficiency (patient who\nis heterozygous for one of the alleles *2A, *13, or\nc.2846A&gt;T), dose should be reduced 50% for the first cycle. If a complete deficiency is demonstrated, fluoropyrimidines are contraindicated due to the risk of fatal toxicity with the standard dose.</p>\n</blockquote>\n<p>While the recommendation section text does not mention Hap3B <a href=\"/variant/PA166153889\">rs56038477</a> it is listed in Table 1 and in Table 3 the diplotype *1/HapB3 is given activity score of 1.5 and 75% of standard dose.</p>\n",
      "version" : 0
    },
    "userId" : "cfthorn",
    "version" : 0
  }
}